AKT1 and neoplasm: Du et al. find that in non-small cell lung cancer, highly expressed PD-L1 enters the nucleus by binding to the nucleoprotein KPNB1, then activates the Gas6/MerTK and its downstream AKT and Erk signaling pathways, thereby promoting tumor cell proliferation [146], offering a novel perspective for the optimization of lung cancer immunotherapy.